SPX3,963.51+29.59 0.75%
DIA338.46+2.02 0.60%
IXIC11,082.00+123.45 1.13%

--Barclays Adjusts Price Target on Revance Therapeutics to $37 From $35, Maintains Overweight Rating

--Barclays Adjusts Price Target on Revance Therapeutics to $37 From $35, Maintains Overweight Rating

MT Newswires · 11/16/2022 04:53

Please log in to view news